Product, Cell Processing was Biolife Solutions’s largest product and service line in fiscal 2024, bringing in $73.45M of $82.25M (89%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Product Revenue | — | — | $68.97M | — | ||||
| Product, Cell Processing | — | $68.51M | $65.77M | $73.45M | ||||
| Cell Processing | $44.97M | — | — | — | ||||
| Freezer & Thaw | $56.62M | — | — | — | ||||
| Product, Freezer & Thaw | — | — | — | — | ||||
| Biopreservation Media | — | — | — | — | ||||
| Service Biostorage Services | $9.82M | — | — | — | ||||
| Rental Biostorage Services | $7.43M | — | — | — | ||||
| Rental, Evo & Thaw | — | $4.22M | $6.54M | $6.07M | ||||
| Regenerative Medicine | — | — | — | — | ||||
| Distribution Service | — | — | — | — | ||||
| Product, Evo & Thaw | — | $3.43M | $3.20M | $2.58M | ||||
| Drug Discovery | — | — | — | — | ||||
| Biobanking | — | — | — | — | ||||
| Rental Revenue | — | — | — | — | ||||
| Product Biostorage Services | $328.00K | — | — | — | ||||
| Service, Evo & Thaw | — | $73.00K | $349.00K | $160.00K | ||||
| Product, Storage & Cold Chain Services | — | — | — | — | ||||
| Service Revenue | — | $73.00K | — | — | ||||
| Total | $119.16M | $76.31M | $144.82M | $82.25M |
Biolife Solutions brought in $82.25M from its four product and service lines in fiscal 2024, the year ended December 31, 2024. Biolife Solutions regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $144.82M. Product, Cell Processing was the largest at $73.45M (89.3%), ahead of Rental, Evo & Thaw at $6.07M (7.4%) and Product, Evo & Thaw at $2.58M (3.1%). The remaining line, Service, Evo & Thaw, brought in $160.00K.
Compared with fiscal 2023, Product, Cell Processing grew fastest, up 11.7% to $73.45M, while Product, Evo & Thaw fell the most, down 19.2% to $2.58M.
Biolife Solutions began breaking out Rental, Evo & Thaw in fiscal 2022, Product, Evo & Thaw in fiscal 2022 and Service, Evo & Thaw in fiscal 2022. Biolife Solutions stopped reporting Product Revenue ($68.97M in fiscal 2023), Freezer & Thaw ($56.62M in fiscal 2021), Cell Processing ($44.97M in fiscal 2021) and four others as separate lines.
Biolife Solutions (BLFS) reports its revenue by product and service. In fiscal 2024, Product, Cell Processing was its largest product and service line, bringing in $73.45M (89.3% of the total), followed by Rental, Evo & Thaw at $6.07M (7.4%).
Product, Cell Processing was Biolife Solutions' largest product and service line in fiscal 2024, bringing in $73.45M, or 89.3% of the $82.25M total across its four product and service lines.
Every figure comes from Biolife Solutions' annual financial filings, as reported. Each line keeps the name Biolife Solutions gives it, and years follow its fiscal calendar.
Biolife Solutions' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.